Advertisement

Clinical Pharmacokinetics

, Volume 40, Supplement 1, pp 39–48 | Cite as

Evaluation of the Influence of Antacids and H2 Antagonists on the Absorption of Moxifloxacin after Oral Administration of a 400mg Dose to Healthy Volunteers

  • Heino Stass
  • Michael-Friedrich Böttcher
  • Klaus Ochmann
Original Research Article

Abstract

Objective

To determine the effect of concomitant administration of the antacid Maalox 70® or the histamine H2 receptor antagonist ranitidine on the bioavailability of moxifloxacin.

Design

These were nonblinded, randomised, crossover studies performed in healthy volunteers.

Participants

24 healthy males aged 22 to 39 years (study 1; n = 12) and 24 to 43 years (study 2; n = 12) were included in these studies.

Methods

In study 1, 12 participants received ranitidine 150mg twice daily during a 3-day pretreatment phase and 1 tablet of ranitidine together with a single 400mg dose of moxifloxacin on the profile day. In study 2, 12 participants received a single 400mg dose of moxifloxacin alone (treatment A), simultaneously with Maalox 70® 10ml (treatment B), or with Maalox 70® 10ml given 4 hours before (treatment C) or 2 hours after (treatment D) the fluoroquinolone. In treatments B, C and D, administration of the antacid (10ml, 1 hour after each meal) was continued for 2 days. Plasma and urine samples were obtained for determination of the pharmacokinetic parameters of moxifloxacin.

Results

Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUC∞) [35.5 versus 34.3 mg/L · h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%]. When moxifloxacin was given simultaneously with Maalox 70®, AUC∞ (14.7 mg/L · h) and Cmax(1.00 mg/L) were reduced by approximately 60%. When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUC∞ values (28.0 and 26.7 versus 34.3 mg/L · h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L). The mean bioavailabilities corrected for the elimination rate constants (λz) were 101% (antacid given 4 hours before moxifloxacin) and 98% (antacid given 2 hours after moxifloxacin), indicating that Maalox 70® may interfere with the gastrointestinal recirculation of moxifloxacin.

Conclusions

The bioavailability of moxifloxacin is not affected by concurrent administration of ranitidine. Absorption of moxifloxacin is impaired by concomitant administration of aluminium- and magnesium-containing antacids and administration of these agents should be staggered. An interval of 2 hours before or 4 hours after taking the antacid ensures that the effect of the interaction is not clinically relevant.

Keywords

Ranitidine Fluoroquinolones Moxifloxacin Enoxacin Relative Bioavailability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors are grateful to Professor A. Dalhoff for contributing the in vitro data used in the modelling studies and for his scientific support during the review of this manuscript. We also express our thanks to Dr S. Wegener for the excellent realisation of the editorial issues as well as to G. Schwarz, P. Hopfe and the medical and laboratory teams for the experimental work in this study. Parts of this paper were presented at the 20th International Congress of Chemotherapy in Sydney in 1997.[38,39]

References

  1. 1.
    Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410–25PubMedCrossRefGoogle Scholar
  2. 2.
    Jacobs E, Dalhoff A, Brunner H. Efficacy of BAY 12-8039 in Mycoplasma pneumoniae infected guinea pigs [abstract no. F17]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana: 102Google Scholar
  3. 3.
    Rouse MS, Piper KE, Patel R, et al. In vitro and in vivo activity of BAY 12-8039 or trovafloxacin against penicillin-resistant Streptococcus pneumoniae experimental pneumonia in immunocompetent mice [abstract no. B45]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana: 29Google Scholar
  4. 4.
    Stass H, Kubitza D, Schühly U, et al. Pharmacokinetics, safety, and tolerability of 800 mg BAY 12-8039 administered orally as a single dose [abstract no. P388]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland. Clin Microbiol Infection 1997; 3 Suppl. 2: 87Google Scholar
  5. 5.
    Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxyquinolone administered to healthy subjects. Antimicrob Agents Chemother 1998; 42(8): 2060–5PubMedGoogle Scholar
  6. 6.
    Stass H, Schiihly U, Wingender W. Pharmacokinetics, safety, and tolerability of 600 mg BAY 12-8039 administered once daily over 10 days [abstract no. P387]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland. Clin Microbiol Infection 1997; 3 Suppl. 2: 87Google Scholar
  7. 7.
    Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxy-quinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163–74PubMedCrossRefGoogle Scholar
  8. 8.
    Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc., 1982Google Scholar
  9. 9.
    Till AE, Benet LZ, Kwan KC. An integrated approach to the pharmacokinetic analysis of drug absorption. J Pharmacokinet Biopharm 1974; 2(6): 525–44PubMedGoogle Scholar
  10. 10.
    Deppermann KM, Lode H. Fluoroquinolones: interaction profile during enterai absorption. Drugs 1993; 45 Suppl. 3: 65–72PubMedCrossRefGoogle Scholar
  11. 11.
    Grasela Jr TH, Schentag JJ, Sedman AJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother 1989; 33: 615–7PubMedCrossRefGoogle Scholar
  12. 12.
    Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption. Clin Pharmacol Ther 1992; 52(3): 252–6PubMedCrossRefGoogle Scholar
  13. 13.
    Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of Ciprofloxacin. Clin Pharmacol Ther 1989; 46(6): 700–5PubMedCrossRefGoogle Scholar
  14. 14.
    Steinijans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharm Ther Tox 1991; 29(8): 323–8Google Scholar
  15. 15.
    Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of Ciprofloxacin. Antimicrob Agents Chemother 1992; 36(4): 830–2PubMedCrossRefGoogle Scholar
  16. 16.
    Lubowski TJ, Nightingale CH, Sweeney K et al. Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. Antimicrob Agents Chemother 1992; 36: 2758–60PubMedCrossRefGoogle Scholar
  17. 17.
    Parpia SH, Nix DE, Hejmanowski LG, et al. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 1989; 33(1): 99–102PubMedCrossRefGoogle Scholar
  18. 18.
    Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother 1992; 36: 1219–24PubMedCrossRefGoogle Scholar
  19. 19.
    Foster TS, Blouin R. The effect of timing on lomefloxacin bioavailability [abstract]. Pharmacotherapy 1991; 11: 101Google Scholar
  20. 20.
    Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother 1990; 34: 432–5PubMedCrossRefGoogle Scholar
  21. 21.
    Flor S, Guay DRP, Opsahl JA, et al. Effects of magnesiumaluminum hydroxide and calcium carbonate antacids on bioavailability of Ofloxacin. Antimicrob Agents Chemother 1990; 34: 2436–8PubMedCrossRefGoogle Scholar
  22. 22.
    Sahai J, Healy DH, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral Ciprofloxacin. Br J Clin Pharmacol 1993; 35(3): 302–4PubMedGoogle Scholar
  23. 23.
    Shiba K, Sakai O, Shimada J, et al. Effect of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother 1992; 36(10): 2270–4PubMedCrossRefGoogle Scholar
  24. 24.
    Campbell NRC, Kara M, Hasinoff BB, et al. Norfloxacin interaction with antacids and minerals. Br J Clin Pharmacol 1992; 33(1): 115–6PubMedCrossRefGoogle Scholar
  25. 25.
    Sahai J, Gallicano K, Oliveras L, et al. Cations in the didanosine tablet reduce Ciprofloxacin bioavailability. Clin Pharmacol Ther 1993; 53(3): 292–7PubMedCrossRefGoogle Scholar
  26. 26.
    Jaehde U, Sörgel F, Stephan U, et al. Effect of an antacid containing magnesium and aluminum on absorption, metabolism and mechanism of renal elimination of Pefloxacin in humans. Antimicrob Agents Chemother 1994; 38(5): 1129–33PubMedCrossRefGoogle Scholar
  27. 27.
    Tuncel T, Bergisadi N. In vitro adsorption of Ciprofloxacin hydrochloride on various antacids. Pharmazie 1992; 47: 304–5Google Scholar
  28. 28.
    Ma HH, Chiu FC, Li RC. Mechanistic investigation of the reduction in antimicrobial activity of Ciprofloxacin by metal cations. Pharm Res 1994; 14(3): 366–70CrossRefGoogle Scholar
  29. 29.
    Zupancic M, Bukovec P. Complexation of magnesium (II) with Ciprofloxacin and norfloxacin. Acta Pharm 1996; 46: 221–8Google Scholar
  30. 30.
    Teixeira MH, Vilas-Boas LF, Gil VM, et al. Complexes of Ciprofloxacin with metal ions contained in antacid drugs. J Chemother 1995; 7(2): 126–32PubMedGoogle Scholar
  31. 31.
    Macias-Sanchez B, Martinez-Cabarga M, Sanchez-Navarro A, et al. Aphysico-chemical study of interaction of Ciprofloxacin and Ofloxacin with polyvalent cations. Int J Pharmaceut 1994; 106: 229–35CrossRefGoogle Scholar
  32. 32.
    Okazaki O, Kurata T, Tachizawa H. Studies on the mechanism of PK interaction of aluminium hydroxide, an antacid, with new quinolones in rats. Xenobiot Metab Dispos 1988; 3: 387–94Google Scholar
  33. 33.
    Lomaestro BM, Bailie GR. Effect of multiple staggered doses of calcium on the bioavailability of Ciprofloxacin. Ann Pharmacother 1993; 27(11): 1325–8PubMedGoogle Scholar
  34. 34.
    Sörgel F, Naber KG, Jaehde U, et al. Brief report: gastrointestinal secretion of Ciprofloxacin, evaluation of the charcoal model for investigations in healthy volunteers. Am J Med 1989; 87 Suppl. 5A: 62S–5PubMedCrossRefGoogle Scholar
  35. 35.
    Teng RL, Dogolo LC, Willavize SA, et al. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother 1994; 39 Suppl. B: 93–7Google Scholar
  36. 36.
    Dalhoff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 1999; 43 Suppl. B: 51–9PubMedCrossRefGoogle Scholar
  37. 37.
    Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections: the role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37(1): 1–16PubMedCrossRefGoogle Scholar
  38. 38.
    Stass H, Ochmann K. Study to evaluate the interaction between BAY 12-8039 and ranitidine [abstract no. 3357]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108Google Scholar
  39. 39.
    Stass H, Böttcher M, Horstmann R. Study to evaluate the interaction between BAY 12-8039 and antacids [abstract no. 3358]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108Google Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Heino Stass
    • 1
  • Michael-Friedrich Böttcher
    • 1
  • Klaus Ochmann
    • 1
  1. 1.Pharma Research Centre, Institute of Clinical PharmacologyBayer AGWuppertalGermany

Personalised recommendations